osiris
-
Osiris Therapeutics receives $15 million cash payment from Mesoblast for Prochymal
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic…
Read More » -
Osiris Therapeutics Announces Therésa K. Dixon as General Manager of Market Access and Reimbursement
COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions…
Read More » -
Osiris Receives Medicare Reimbursement Codes for Grafix(R)
COLUMBIA, Md., May 29, 2012 (BUSINESS WIRE) — Osiris Therapeutics, Inc. OSIR +3.34% , the leading stem cell company focused on developing and…
Read More » -
Biologics
Osiris Therapeutics Strengthens Senior Management Team
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced the appointment of Stephen W. Potter as Senior Vice President of…
Read More » -
Prochymal New Drug Submission Granted Priority Review by Health Canada
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its…
Read More » -
Osiris Therapeutics Reports First Quarter 2010 Financial Results
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell therapeutic company focused on developing and marketing products to…
Read More » -
Osiris Therapeutics Receives FDA Orphan Drug Designation for Stem Cell Treatment for Type 1 Diabetes
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has been granted Orphan Drug designation from the U.S. Food…
Read More » -
Osiris Receives Milestone Payment for Prochymal Development Progress in Japan
COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that it has achieved a $1 million milestone payment from its Japanese commercial…
Read More »